These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25256026)

  • 1. The therapeutic landscape for hereditary angioedema: more change on the horizon?
    Riedl MA
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):337-8. PubMed ID: 25256026
    [No Abstract]   [Full Text] [Related]  

  • 2. Hereditary angioedema--therapies old and new.
    Morgan BP
    N Engl J Med; 2010 Aug; 363(6):581-3. PubMed ID: 20818894
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic agents for hereditary angioedema.
    Giavina-Bianchi P; Motta A; Kalil J
    N Engl J Med; 2011 Jan; 364(1):85; author reply 86. PubMed ID: 21208116
    [No Abstract]   [Full Text] [Related]  

  • 4. Ecallantide for the treatment of acute attacks in hereditary angioedema.
    Cicardi M; Levy RJ; McNeil DL; Li HH; Sheffer AL; Campion M; Horn PT; Pullman WE
    N Engl J Med; 2010 Aug; 363(6):523-31. PubMed ID: 20818887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA approves kallikrein inhibitor to treat hereditary angioedema.
    Thompson CA
    Am J Health Syst Pharm; 2010 Jan; 67(2):93. PubMed ID: 20065259
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks.
    Kuhlen J; Guyer A; Morphew T; Tachdjian R; Banerji A
    Ann Allergy Asthma Immunol; 2014 May; 112(5):471-2. PubMed ID: 24630437
    [No Abstract]   [Full Text] [Related]  

  • 7. Response time for ecallantide treatment of acute hereditary angioedema attacks.
    Riedl M; Campion M; Horn PT; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Dec; 105(6):430-436.e2. PubMed ID: 21130380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of ecallantide to treat a hereditary angioedema attack after failure of C1 inhibitor prophylaxis.
    Burke S; Petrov A; Johnson J; MacGinnitie A
    Ann Allergy Asthma Immunol; 2011 Aug; 107(2):181-2. PubMed ID: 21802029
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase 1 study investigating DX-2930 in healthy subjects.
    Chyung Y; Vince B; Iarrobino R; Sexton D; Kenniston J; Faucette R; TenHoor C; Stolz LE; Stevens C; Biedenkapp J; Adelman B
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):460-6.e2. PubMed ID: 24980392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of ecallantide in pediatric hereditary angioedema.
    MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
    Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the management of hereditary angioedema.
    Hemperly SE; Agarwal NS; Xu YY; Zhi YX; Craig TJ
    J Am Osteopath Assoc; 2013 Jul; 113(7):546-55. PubMed ID: 23843378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Berotralstat (Orladeyo) for prevention of hereditary angioedema.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e7-e8. PubMed ID: 34544111
    [No Abstract]   [Full Text] [Related]  

  • 13. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.
    LANDERMAN NS; WEBSTER ME; BECKER EL; RATCLIFFE HE
    J Allergy; 1962; 33():330-41. PubMed ID: 14461960
    [No Abstract]   [Full Text] [Related]  

  • 14. An evidence based therapeutic approach to hereditary and acquired angioedema.
    Bork K
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
    Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
    Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ecallantide for treatment of acute attacks of hereditary angioedema.
    Martello JL; Woytowish MR; Chambers H
    Am J Health Syst Pharm; 2012 Apr; 69(8):651-7. PubMed ID: 22472866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
    Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
    Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
    Banta E; Horn P; Craig TJ
    Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hereditary angioedema--treatment].
    Muszyńska A; Fal AM
    Pol Merkur Lekarski; 2008 Jul; 25(145):94-6. PubMed ID: 18839625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.